| Title |
A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease
|
|---|---|
| Published in |
Psychopharmacology, October 2009
|
| DOI | 10.1007/s00213-009-1706-1 |
| Pubmed ID | |
| Authors |
Shahin Akhondzadeh, Mehdi Shafiee Sabet, Mohammad Hossein Harirchian, Mansoreh Togha, Hamed Cheraghmakani, Soodeh Razeghi, Seyyed Shamssedin Hejazi, Mohammad Hossein Yousefi, Roozbeh Alimardani, Amirhossein Jamshidi, Shams-Ali Rezazadeh, Aboulghasem Yousefi, Farhad Zare, Atbin Moradi, Ardalan Vossoughi |
| Abstract |
There is increasing evidence to suggest the possible efficacy of Crocus sativus (saffron) in the management of Alzheimer's disease (AD). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 206 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| Greece | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 202 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 32 | 16% |
| Researcher | 27 | 13% |
| Student > Bachelor | 24 | 12% |
| Student > Ph. D. Student | 21 | 10% |
| Other | 12 | 6% |
| Other | 37 | 18% |
| Unknown | 53 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 19% |
| Agricultural and Biological Sciences | 23 | 11% |
| Biochemistry, Genetics and Molecular Biology | 15 | 7% |
| Neuroscience | 12 | 6% |
| Nursing and Health Professions | 11 | 5% |
| Other | 44 | 21% |
| Unknown | 61 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2022.
All research outputs
#1,105,311
of 22,962,258 outputs
Outputs from Psychopharmacology
#274
of 5,364 outputs
Outputs of similar age
#3,027
of 94,222 outputs
Outputs of similar age from Psychopharmacology
#3
of 21 outputs
Altmetric has tracked 22,962,258 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,364 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 94,222 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.